Compare AAME & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | GANX |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | AAME | GANX |
|---|---|---|
| Price | $2.42 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 25.5K | ★ 1.2M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $208,218,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.91 | ★ N/A |
| Revenue Growth | ★ 11.99 | N/A |
| 52 Week Low | $1.25 | $1.41 |
| 52 Week High | $3.71 | $4.34 |
| Indicator | AAME | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 67.19 |
| Support Level | $2.34 | $3.94 |
| Resistance Level | $2.62 | $4.34 |
| Average True Range (ATR) | 0.15 | 0.39 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 61.21 | 71.00 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.